TAMS may reduce CD8+ T cell motility and confine them to the stroma and may contribute to ECM remodeling and disruption of its stiffness, thus limiting immune cell infiltration into the tumor and decreasing the therapeutic impact of ICIs [30–32]. Here, CD8A is linked to neoplasm.